In Vitro and In Vivo Efficacy of CD38 Directed Therapy with Daratumumab In the Treatment of Multiple Myeloma

被引：0
|
作者：
Groen, Richard W. [1 ]
van der Veer, Michael [1 ]
Hofhuis, Frans M. [1 ]
van Kessel, Berris [1 ]
de Weers, Michel [2 ]
Parren, Paul W. H. I. [2 ]
Lokhorst, Henk M. [1 ]
Mutis, Tuna [1 ]
Martens, Anton [1 ]
机构：
[1] UMC Utrecht, Utrecht, Netherlands
[2] Genmab BV, Utrecht, Netherlands
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1261 / 1262
页数：2
相关论文
共 50 条
  • [21] CD38 directed multi-agent therapy is feasible and shows efficacy in CD38 pretreated rrMM
    Steinhardt, M.
    Krummenast, F. C.
    Zhou, X.
    Lapa, C.
    Dierks, A.
    Heidemeier, A.
    Einsele, H.
    Rasche, L.
    Kortuem, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 278 - 279
  • [22] Anti CD38 monoclonal antibodies for multiple myeloma treatment
    Gozzetti, Alessandro
    Ciofini, Sara
    Simoncelli, Martina
    Santoni, Adele
    Pacelli, Paola
    Raspadori, Donatella
    Bocchia, Monica
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (05)
  • [23] Daratumumab induces CD38 internalization and impairs myeloma cell adhesion
    Ghose, Jayeeta
    Viola, Domenico
    Terrazas, Cesar
    Caserta, Enrico
    Troadec, Estelle
    Khalife, Jihane
    Gunes, Emine Gulsen
    Sanchez, James
    McDonald, Tinisha
    Marcucci, Guido
    Kaur, Balveen
    Rosenzweig, Michael
    Keats, Jonathan
    Rosen, Steven
    Krishnan, Amrita
    Satoskar, Abhay R.
    Hofmeister, Craig C.
    Pichiorri, Flavia
    ONCOIMMUNOLOGY, 2018, 7 (10):
  • [24] Ex Vivo Activity of Immunotherapeutic Approaches Targeting CD38 Against Daratumumab-Resistant Multiple Myeloma Patient Samples
    Karvouni, Maria
    Zhou, Heyue
    Kathleen, Arnika
    Ma, Qiangzhong
    Baloch, Alamdar H.
    Zhu, Tong
    Zhang, Hong
    Gilljam, Mari
    Lundqvist, Andreas
    Kaufmann, Gunnar F.
    Alici, Evren
    BLOOD, 2019, 134
  • [25] CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies
    de Acha, Olivia Perez
    Reiman, Lauren
    Jayabalan, David S.
    Walker, Zachary J.
    Bosma, Grace
    Keller, Alana L.
    Parzych, Sarah E.
    Abbott, Diana
    Idler, Beau M.
    Ribadeneyra, Drew
    Niesvizky, Ruben
    Forsberg, Peter A.
    Mark, Tomer M.
    Sherbenou, Daniel W.
    BLOOD ADVANCES, 2023, 7 (21) : 6430 - 6440
  • [26] Immunotherapies targeting CD38 in Multiple Myeloma
    Atanackovic, Djordje
    Steinbach, Mary
    Radhakrishnan, Sabarinath Venniyil
    Luetkens, Tim
    ONCOIMMUNOLOGY, 2016, 5 (11):
  • [27] CD38 as an immunotherapeutic target in multiple myeloma
    Bonello, Francesca
    D'Agostino, Mattia
    Moscvin, Maria
    Cerrato, Chiara
    Boccadoro, Mario
    Gay, Francesca
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (12) : 1209 - 1221
  • [28] DARATUMUMAB Anti-CD38 Monoclonal Antibody, Treatment of Multiple Myeloma
    Richardson, P.
    Lokhorst, H.
    Palumbo, A.
    Nahi, H.
    Laubach, J.
    Gimsing, P.
    Lisby, S.
    Cakana, A.
    Brun, N. Constantin
    Plesner, T.
    DRUGS OF THE FUTURE, 2013, 38 (08) : 545 - 554
  • [29] Patient multiple myeloma cells do not express targetable levels of CD38 when in remission on daratumumab
    Reiman, Lauren
    de Acha, Olivia Perez
    Jayabalan, David
    Walker, Zachary
    Bosma, Grace
    Abbott, Diana
    Ribadeneyra, Drew
    Niesvizky, Ruben
    Mark, Tomer
    Forsberg, Peter
    Sherbenou, Daniel
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S53 - S54
  • [30] Preclinical Development of Near-Infrared-Labeled CD38-Targeted Daratumumab for Optical Imaging of CD38 in Multiple Myeloma
    Cho, Nicholas
    Ko, Sooah
    Shokeen, Monica
    MOLECULAR IMAGING AND BIOLOGY, 2021, 23 (02) : 186 - 195
12345